Panflu is claimed to be the first and only approved vaccine available in China against the H5N1 influenza virus. The vaccine is approved for production solely to be supplied to the Chinese national vaccine stockpiling program and will not be sold directly to the market. The license also indicates that the Chinese government has the exclusive right to initiate Panflu vaccinations in an emergency or in the event of an influenza pandemic.
Weidong Yin, chairman, president and CEO of Sinovac, said: “The government of China has indicated publicly their intention to stockpile the vaccine in advance of the Olympic games in Beijing this summer. Sinovac is committed to working closely with the regulators and the government to develop and implement the national stockpiling program for the pandemic influenza vaccine.”